A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group

Epilepsy Research
R KälviäinenK Lyby

Abstract

In a multicentre, double-blind, parallel-group, placebo-controlled trial, a three-times daily regimen of tiagabine was evaluated as add-on therapy in 154 adult patients with refractory partial seizures. A total of 77 patients were randomised to treatment in each arm. Tiagabine HCl was titrated from an initial dose of 12-30 mg/day over 4 weeks. During the 12-week fixed-dose period, there was a significant reduction in the median 4-weekly seizure rate for all partial seizures and simple partial seizures (P < 0.05 in each case). Furthermore, the proportion of patients with a reduction of 50% or more in all partial seizures was higher in the tiagabine group than in the placebo group (14 versus 6%), though the difference did not achieve statistical significance. The difference with respect to simple partial seizures was significant (21 versus 6%, P < 0.01). The percentage of patients achieving an increase of at least 50% in the proportion of days free of all partial seizures was significantly greater in the tiagabine group compared to placebo (14 versus 4%, P<0.01). Tiagabine did not appear to influence the plasma concentrations of other concomitant antiepileptic drugs and was generally well tolerated, with most drug-related adverse...Continue Reading

References

Apr 24, 1991·European Journal of Pharmacology·E B NielsenC Braestrup
Jul 28, 1990·Lancet·B S Meldrum
Jan 1, 1995·Epilepsia·I E Leppik
Jan 1, 1995·Epilepsia·E Ben-Menachem
Mar 31, 1999·American Journal of Therapeutics·L E GustavsonK W Sommerville
Mar 31, 1999·American Journal of Therapeutics·L E GustavsonG R Granneman

❮ Previous
Next ❯

Citations

Jul 23, 2003·Pharmacology, Biochemistry, and Behavior·Jarogniew ŁuszczkiStanisław J Czuczwar
Aug 25, 2001·Epilepsia·R Kälviäinen
Oct 26, 1999·Epilepsia·S C Schachter
Nov 24, 1999·Epilepsia·J M Rho, R Sankar
Sep 30, 2005·Epilepsia·Matthias J KoeppShelagh Smith
Feb 5, 1998·Lancet·J P Leach, M J Brodie
Dec 14, 2002·Bipolar Disorders·Trisha SuppesRobert M Post
May 7, 2014·Expert Opinion on Pharmacotherapy·Sylvain Rheims, Philippe Ryvlin
Nov 19, 2009·Epilepsy & Behavior : E&B·A B GuekhtE I Gusev
Dec 14, 2002·Mayo Clinic Proceedings·Joseph I Sirven
Mar 16, 2001·Expert Opinion on Pharmacotherapy·P H McCabe
May 5, 2001·Expert Opinion on Pharmacotherapy·S C Schachter
Feb 9, 2007·Mayo Clinic Proceedings·Joseph I SirvenJoseph F Drazkowski
Sep 14, 2000·Seizure : the Journal of the British Epilepsy Association·T FakhouryB Abou-Khalil
May 12, 2004·Epilepsy Research·Claudia Stöllberger, Josef Finsterer
Dec 27, 2016·Seizure : the Journal of the British Epilepsy Association·Ambica Golyala, Patrick Kwan
Sep 15, 2005·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Neil HawkinsMark Sculpher
Aug 1, 2011·Therapeutic Advances in Drug Safety·Jacqueline A French, Deana M Gazzola
Jul 22, 2011·Journal of Human Genetics·Dong-Uk KimMin-Cheol Lee
Jul 3, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Marco Mula, Josemir W Sander
Jul 17, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jarogniew J LuszczkiStanisław J Czuczwar
Dec 21, 2000·Current Psychiatry Reports·L S Goldman
Feb 7, 2014·The Cochrane Database of Systematic Reviews·Jennifer PulmanAnthony G Marson
Nov 7, 2007·CNS Spectrums·Jennifer M Rosenberg, Carl Salzman
Oct 15, 2019·The Cochrane Database of Systematic Reviews·Rebecca BresnahanAnthony G Marson
Nov 3, 2004·Seizure : the Journal of the British Epilepsy Association·Xiaolan WangPhilip N Patsalos
Jul 6, 2021·Revue neurologique·M Bou NasifN J Azar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.